We exist to move medical research forward — toward the discoveries and cures the evidence is already pointing at.
At the frontier, the science arrives faster than anyone can synthesize it, and the breakthroughs hiding in the connections between hundreds of papers go unmade. ZemiResearch builds the synthesized base that makes the next discovery possible.
Our mission
ZemiResearch exists to accelerate frontier medical research toward new discoveries and cures. The breakthroughs the field needs are often not waiting on one more experiment — they are waiting on someone to connect what hundreds of separate papers, trials, and registries already imply, and to turn that into something a team can act on and build from.
So we build that base. We are a research company founded on one conviction: at the frontier, the scarce thing is not information — it is verified synthesis. Hundreds of sources, read together and reconciled honestly, reveal the couplings, gaps, and testable ideas no single reader could assemble. That synthesized base is what lets a developer, investor, or scientist move faster — and, as our own published work shows, carry an idea past the literature into genuinely new findings.
The method is the credibility.
We don't ask buyers to trust us. We build the work so it can be checked.
Synthesis no single reader can match
Hundreds of papers, trials, registries, regulatory records, and company signals per dossier — read and reconciled into one decision map.
Every claim graded, not asserted
Each is labeled by evidence layer — established, inferred, hypothetical, or quarantined — carries a verbatim source excerpt, and is retraction-checked. Zero retractions across the catalog.
Predictions, not promotion
Each dossier converts its thesis into explicit, pre-powered hypotheses with named kill-switches — so the work can be tested rather than believed.
Pre-registered and open
When we test a claim ourselves, we register the plan first and publish the code and the result — whatever it shows. Two preprints so far, both on Zenodo.
AI research system, human-verified
Scale comes from an AI research system; accountability, source-checking, and honest labeling come from a named author who signs the work. No AI is an author.
Carried toward the clinic
When a buyer needs more than the map, our Clinical Trial Blueprint carries one hypothesis to a pre-IND-ready trial design.
The Evidence & Decision Workbook — 30 to 45 live sheets you operate, not just read.
The report is the argument; the workbook is the machine underneath it — an auditable evidence system plus two working tools, in one spreadsheet a buyer drives with their own numbers.
Every claim, traced to its source
Claim Ledger, Evidence Table, Source-Support Verdicts (six-way: supports exactly / partially / contradicts / insufficient), Source-Quality Summary, and a Traceability Certificate — each claim carrying a verbatim excerpt and identifier, retraction-checked.
Power Calculations you re-run
Every hypothesis rendered as live NORM.S.INV sample-size formulas with per-effect sensitivity bands and a cached-vs-live integrity check. Change the effect, control rate, or alpha and every required n recomputes — model your own program in the first meeting.
A 9-sheet decision tool
Enter your program's profile and the classifier returns the binding (rate-limiting) node, the matched strategy, the required assay panel, and a safety-critical contraindication — with its own decision rules, organ rules, archetype cards, validation log, and traceability map.
The field, mapped
Asset & company tracker, trial-catalyst tracker, competitive landscape, regulatory-endpoint tracker, organ-strategy and cross-transfer matrices, and biomarker maps — the moving pieces of the field, sourced and current.
13+ falsifiable, pre-powered
A Hypotheses Ledger and a Most-Valuable-Next-Studies sheet: each hypothesis couples ≥2 mechanisms, predicts a readout, names its explicit disconfirming test, and pairs with a costed, powered next study.
The work you usually never see
Excluded-claims and quarantined-source registers, a salvage ledger, a full verification & search log, a figure source map, a version registry, and an audit issues log — the discarded and contested material kept in the open.
What we are — and what we are not
ZemiResearch produces frontier translational strategy and hypothesis generation, for research use only. It is not clinical guidance or investment advice, and it never claims a hypothesis is proven. On the contrary — the discipline of saying plainly what is established, what is inferred, and what remains unproven is the product. Sophisticated buyers do not need to be told a story; they need to be handed something they can interrogate.
ZemiResearch is a venture of Reyes Financial, LLC (Dorado, Puerto Rico), founded by Delfin Reyes. Published research is registered under ORCID 0009-0003-6683-9335 and released open-access under CC BY 4.0.
Tell us about your program.
Buy a dossier, ask which one fits, scope a custom dossier, or commission a Clinical Trial Blueprint — it all starts with a conversation.